ClinicalTrials.gg

Program

AERO-002

A development code. Also written as “AERO-002 (60 mcg)”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by AeroRx Therapeutics.

Furthest: phase 2, since Feb 14, 20253 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AeroRx Therapeutics31 open or runningphase 2since Feb 14, 2025Feb 14, 2025Jun 2027phase 2 · NCT07896252

Also a collaborator on its studies: medicines-evaluation-unit-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 14, 2025First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT06841640 · 24 enrolled · United Kingdom
  2. Aug 29, 2026Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07802730 · 24 enrolled · United Kingdom
  3. Oct 14, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07896252 · 64 planned · United Kingdom

Ahead

  1. Jun 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07896252

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07896252Pulmonary Disease, Chronic Obstructive · United Kingdom2RecruitingJun 202764
NCT07802730Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedOct 9, 202624
NCT06841640Pulmonary Disease, Chronic Obstructive · United Kingdom2CompletedMay 20, 202524

How it is read

Names in the registry

  • “AERO-002”, 2 entries
  • “AERO-002 (60 mcg)”, 1 entry

Codes read as this program: AERO002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.